Suppr超能文献

白色念珠菌和非白色念珠菌引起的侵袭性念珠菌病初始治疗抗真菌疗法的药物经济学分析

Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.

作者信息

Ou Huang-Tz, Lee Tsung-Ying, Chen Yee-Chun, Charbonneau Claudie

机构信息

Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Department of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

出版信息

BMC Infect Dis. 2017 Jul 10;17(1):481. doi: 10.1186/s12879-017-2573-8.

Abstract

BACKGROUND

Cost-effectiveness studies of echinocandins for the treatment of invasive candidiasis, including candidemia, are rare in Asia. No study has determined whether echinocandins are cost-effective for both Candida albicans and non-albicans Candida species. There have been no economic evaluations that compare non-echinocandins with the three available echinocandins. This study was aimed to assess the cost-effectiveness of individual echinocandins, namely caspofungin, micafungin, and anidulafungin, versus non-echinocandins for C. albicans and non-albicans Candida species, respectively.

METHODS

A decision tree model was constructed to assess the cost-effectiveness of echinocandins and non-echinocandins for invasive candidiasis. The probability of treatment success, mortality rate, and adverse drug events were extracted from published clinical trials. The cost variables (i.e., drug acquisition) were based on Taiwan's healthcare system from the perspective of a medical payer. One-way sensitivity analyses and probability sensitivity analyses were conducted.

RESULTS

For treating invasive candidiasis (all species), as compared to fluconazole, micafungin and caspofungin are dominated (less effective, more expensive), whereas anidulafungin is cost-effective (more effective, more expensive), costing US$3666.09 for each life-year gained, which was below the implicit threshold of the incremental cost-effectiveness ratio in Taiwan. For C. albicans, echinocandins are cost-saving as compared to non-echinocandins. For non-albicans Candida species, echinocandins are cost-effective as compared to non-echinocandins, costing US$652 for each life-year gained. The results were robust over a wide range of sensitivity analyses and were most sensitive to the clinical efficacy of antifungal treatment.

CONCLUSIONS

Echinocandins, especially anidulafungin, appear to be cost-effective for invasive candidiasis caused by C. albicans and non-albicans Candida species in Taiwan.

摘要

背景

在亚洲,棘白菌素类药物用于治疗包括念珠菌血症在内的侵袭性念珠菌病的成本效益研究较为罕见。尚无研究确定棘白菌素类药物对白色念珠菌和非白色念珠菌是否具有成本效益。也没有经济评估比较非棘白菌素类药物与三种可用的棘白菌素类药物。本研究旨在分别评估卡泊芬净、米卡芬净和阿尼芬净这三种棘白菌素类药物与非棘白菌素类药物相比,对白色念珠菌和非白色念珠菌的成本效益。

方法

构建决策树模型以评估棘白菌素类药物和非棘白菌素类药物治疗侵袭性念珠菌病的成本效益。治疗成功率、死亡率和药物不良事件的概率从已发表的临床试验中提取。成本变量(即药物采购)基于台湾医疗保健系统,从医疗支付者的角度考虑。进行了单因素敏感性分析和概率敏感性分析。

结果

对于治疗侵袭性念珠菌病(所有菌种),与氟康唑相比,米卡芬净和卡泊芬净处于劣势(效果较差,成本更高),而阿尼芬净具有成本效益(效果更好,成本更高),每获得一个生命年的成本为3666.09美元,低于台湾增量成本效益比的隐含阈值。对于白色念珠菌,与非棘白菌素类药物相比,棘白菌素类药物具有成本节约优势。对于非白色念珠菌,与非棘白菌素类药物相比,棘白菌素类药物具有成本效益,每获得一个生命年的成本为652美元。在广泛的敏感性分析中,结果具有稳健性,并且对抗真菌治疗的临床疗效最为敏感。

结论

在台湾,棘白菌素类药物,尤其是阿尼芬净,对于由白色念珠菌和非白色念珠菌引起的侵袭性念珠菌病似乎具有成本效益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3ca/5504557/0e7c30ed0f73/12879_2017_2573_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验